Evidence map›Paper›PMID 28371277›Full record

ArticleJournal of cellular and molecular medicine2017

Overexpression of microRNA-138 alleviates human coronary artery endothelial cell injury and inflammatory response by inhibiting the PI3K/Akt/eNOS pathway.

Jing-Bo Li, Hai-Yang Wang, Ye Yao, Qing-Feng Sun, Zong-Hong Liu, Si-Qi Liu, Jun-Li Zhuang, Yun-Peng Wang, Hong-Yu Liu

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. The Role of miR-138 in Cardiovascular Diseases.BioMed research international · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. CORRIGENDUM.Journal of cellular and molecular medicine · 2020
    Article
  15. Article
  16. Article
  17. Article
  18. Galectin-3 Is a Potential Mediator for Atherosclerosis.Journal of immunology research · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jing-Bo LiDepartment of Cardiac Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Hai-Yang WangDepartment of Vascular Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Ye YaoDepartment of Vascular Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Qing-Feng SunDepartment of Vascular Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Zong-Hong LiuDepartment of Cardiac Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Si-Qi LiuDepartment of Vascular Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Jun-Li ZhuangDepartment of Vascular Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Yun-Peng WangDepartment of Vascular Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Hong-Yu LiuDepartment of Cardiac Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
First Affiliated Hospital of Harbin Medical University · CNHarbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate the role of miR-138 in human coronary artery endothelial cell (HCAEC) injury and inflammatory response and the involvement of the PI3K/Akt/eNOS signalling pathway. Oxidized low-density lipoprotein (OX-LDL)-induced HCAEC injury models were established and assigned to blank, miR-138 mimic, miR-138 inhibitor, LY294002 (an inhibitor of the PI3K/Akt/eNOS pathway), miR-138 inhibitor + LY294002 and negative control (NC) groups. qRT-PCR and Western blotting were performed to detect the miR-138, PI3K, Akt and eNOS levels and the protein expressions of PI3K, Akt, eNOS, p-Akt, p-eNOS, Bcl-2, Bax and caspase-3. ELISAs were employed to measure the expressions of TNF-α, IL-4, IL-6, IL-8, IL-10 and nitric oxide (NO) and the activities of lactate dehydrogenase (LDH) and eNOS. MTT and flow cytometry were performed to assess the proliferation and apoptosis of HCAECs. Compared to the blank group, PI3K, Akt and eNOS were down-regulated in the miR-138 mimic and LY294002 groups but were up-regulated in the miR-138 inhibitor group. The miR-138 mimic and LY294002 groups showed decreased concentrations of TNF-α, IL-6, IL-8 and NO and reduced activities of LDH and eNOS, while opposite trends were observed in the miR-138 inhibitor group. The concentrations of IL-4 and IL-10 increased in the miR-138 mimic and LY294002 groups but decreased in the miR-138 inhibitor group. The miR-138 mimic and LY294002 groups had significantly decreased cell proliferation and increased cell apoptosis compared to the blank group. These findings indicate that up-regulation of miR-138 alleviates HCAEC injury and inflammatory response by inhibiting the PI3K/Akt/eNOS signalling pathway.

Indexed as

AntagomirsApoptosisbcl-2-Associated X ProteinCaspase 3Cell LineCell ProliferationChromonesCoronary VesselsEndothelial CellsGene Expression RegulationHumansInterleukinsLipoproteins, LDLMicroRNAsMorpholinesNitric Oxide Synthase Type III2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-oneAntagomirsbcl-2-Associated X ProteinBCL2 protein, humanCASP3 protein, humanCaspase 3ChromonesInterleukinsLipoproteins, LDLMicroRNAsMIRN138 microRNA, humanMorpholinesNitric Oxide Synthase Type IIINOS3 protein, humanoxidized low density lipoproteinPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2Tumor Necrosis Factor-alphahuman coronary artery endothelial cellsinflammatory responsemicroRNA-138PI3K/Akt/eNOS signalling pathway

Identifiers

PMID28371277
PMCPMC5542903
OpenAlexW2604897934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.